Problems viewing this newsletter? View it in your browser >

Dear Advocate,

Next week, on Wednesday, October 3 at 10am US Eastern, AVAC will host a webinar to discuss the expanding PrEP research pipeline, including intermittent and non-tenofovir-based PrEP. We hope you will join us!

Beyond Daily TDF/FTC as PrEP: Exploring new drugs and regimens for PrEP
On Wednesday, October 3rd from 10–11am US Eastern (check the time in your area at, PrEP researchers will discuss ongoing trials of new oral PrEP interventions, including non-daily regimens (also described as “intermittent PrEP”) and new PrEP drugs such as maraviroc. Joining us will be principal investigators Bob Grant (ADAPT), Ken Mayer (NEXT-PrEP), Sheena McCormack (PROUD) and Jean-Michel Molina (ANRS Ipergay).

These trials all seek to answer questions about strategies other than FDA-approved daily oral TDF/FTC and will provide important information on potential “second-generation” oral PrEP. The webinar will include short presentations from each researcher and a moderated Q&A period. Please join us! 

Register here.

This webinar follows last week’s webinar on the implications of recent regulatory and guidance developments around daily TDF/FTC as PrEP. Speakers and advocates discussed guidelines and guidance documents on daily TDF/FTC as PrEP from the US CDC, the World Health Organization, the Southern African HIV Clinicians Society, the British HIV Association and the British Association for Sexual Health, Gilead Sciences as well as the recent FDA approval of TDF/FTC as PrEP. Audio and slides from this webinar are available here.

If you have any questions please be in touch!


Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 

Contact Us T: +1 212 796 6423